| Literature DB >> 27101004 |
Alexandra D Frolkis1,2, Jennifer de Bruyn2,3, Nathalie Jette2,4, Mark Lowerison2,4, Jordan Engbers2,4, William Ghali1,2, James D Lewis5, Isabelle Vallerand2,4, Scott Patten2,4, Bertus Eksteen1, Cheryl Barnabe1,2, Remo Panaccione1, Subrata Ghosh1, Samuel Wiebe2,4, Gilaad G Kaplan1,2.
Abstract
OBJECTIVES: We assessed the association of smoking at diagnosis of inflammatory bowel disease (IBD) on the need for an intestinal resection.Entities:
Year: 2016 PMID: 27101004 PMCID: PMC4855162 DOI: 10.1038/ctg.2016.21
Source DB: PubMed Journal: Clin Transl Gastroenterol ISSN: 2155-384X Impact factor: 4.488
Patient characteristics of Crohn's disease and ulcerative colitis patients
| 17–40 years | 66.4 | 46.4 |
| >40 years | 33.6 | 53.6 |
| Female | 58.8 | 51.1 |
| Male | 41.2 | 48.9 |
| Never-smoker | 44.6 | 50.1 |
| Ex-smoker | 11.2 | 19.3 |
| Current-smoker | 18.7 | 8.6 |
| Unclassifiable | 25.5 | 22.1 |
| Corticosteroid | 37.4 | 45.1 |
| Immunomodulator | 31.7 | 18.4 |
| <10 mg/l | 63.4 | 77.8 |
| ≥10 mg/l | 36.6 | 22.2 |
| Median (Q1, Q3) | 4.6 (2.7, 7.4) | 5.4 (3.2, 7.9) |
Patients were smokers; however, we were unable to classify as current- or ex-smoker at diagnosis of Crohn's disease.
Corticosteroid use within 90 days of index.
Immunomodulator use for 6 months before surgery, but does not include anti-tumor necrosis factor therapies.
C-reactive protein (CRP) was analyzed in a subset of Crohn's disease (n=1132) and ulcerative colitis (n=2585) patients with available data on CRP after the diagnosis of inflammatory bowel disease (IBD).
Years from disease diagnosis until first surgery or study end.
Figure 1Proportion of patients without a prior history of smoking prior to the diagnosis of inflammatory bowel disease (IBD). The rate of never-smokers at diagnosis significantly increased over time for Crohn's disease (incidence rate ratio (IRR): 1.03; 95% CI: 1.02–1.05), but not for ulcerative colitis (IRR: 1.01; 95% confidence of interval (CI): 1.00–1.01).
Adjusted hazard ratios (HR) for risk of first intestinal resection for Crohn's disease and ulcerative colitis, stratified by age at diagnosis
| Never-smoker | ||||
| Ex-smoker | 0.99 (0.57–1.72) | 1.37 (0.57–3.29) | 1.66 (1.04–2.66) | 1.25 (0.77–2.04) |
| Current-smoker | 0.85 (0.55–1.29) | 2.99 (1.52–5.92) | 0.37 (0.14–1.01) | 1.64 (0.85–3.16) |
| Female | ||||
| Male | 1.14 (0.80–1.62) | 1.10 (0.59–2.06) | 1.12 (0.76–1.64) | 1.95 (1.21–3.15) |
| No | ||||
| Yes | 1.52 (1.07–2.15) | 2.21 (1.18–4.12) | 1.84 (1.25–2.73) | 2.38 (1.48–3.81) |
| No | ||||
| Yes | 0.52 (0.35–0.77) | 0.58 (0.26–1.27) | 0.63 (0.39–1.01) | 1.46 (0.87–2.44) |
CI, Confidence interval.
Referent.
Corticosteroid use within 90 days of index.
Immunosuppressant use for at least 6 months before surgery.
Sensitivity analyses for the association between current smoking and risk of first intestinal resection in Crohn's disease and the association between ex-smoking and risk of colectomy in ulcerative colitis
| Subset of patients with CRP | 0.93 (0.59–1.47) | 2.65 (1.24–5.67) | 1.51 (0.90–2.53) | 1.09 (0.63–1.86) |
| Includes IBD patients who smoked, but were not classified as current or ex-smokers at the index date | 0.87 (0.62–1.23) | 2.95 (1.56–5.58) | 1.12 (0.75–1.67) | 1.41 (0.94–2.14) |
| Backward washout period defined as 5 years | 0.85 (0.55–1.30) | 3.16 (1.58–6.32) | 1.58 (0.97–2.57) | 1.20 (0.72–1.97) |
CI, Confidence of interval; CRP, C-reactive protein; IBD, inflammatory bowel disease.
Cox proportional hazard model is adjusted for CRP, sex, immunosuppressants, and corticosteroids.
Cox proportional hazard model is adjusted for sex, immunosuppressants, and corticosteroids.
Minimum registry in THIN for 5 years before index.
A total of 1-, 3-, and 5-year risk of surgery stratified by age at diagnosis for Crohn's disease and ulcerative colitis.
| 1-year risk (%) | 8.61 (7.02–10.54) | 4.63 (3.10–6.88) | 2.85 (2.15–3.77) | 1.52 (1.06–2.18) |
| 3-year risk (%) | 13.67 (11.65–16.01) | 9.76 (7.42–12.78) | 5.47 (4.45–6.70) | 4.20 (3.37–5.23) |
| 5-year risk (%) | 17.95 (15.54–20.69) | 11.61 (8.95–14.98) | 7.61 (6.33–9.12) | 5.97 (4.93–7.22) |